Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer
6658.0000 42.00 (0.63%)
NSE Jun 27, 2025 15:31 PM
Volume: 545.2K
 

6658.00
0.63%
ICICI Securities Limited
Divi’s Laboratories’ (Divi’s) Q1FY25 result was sub-par. Revenue traction was driven by custom synthesis (CS) (up ~46% YoY), while generics grew 1.5% YoY due to double-digit price erosion in key products like Naproxen, Gabapentin and Dexamethasone.
Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.
More from Divi's Laboratories Ltd.
Recommended